Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors
NCT00393861Phase 2Completed
- Sponsor
- Indiana University
- Start
- Oct 2006
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in germ cell tumor (GCT), sponsored by Indiana University. Primary endpoint: Twelve Month Disease-free Survival Rate at 12 months. Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00393861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393861.